Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777653 | 0.89 | CYP2C19 (0.48) | CYP2C19POLBBLMATM | |
| SCHEMBL5596697 | 0.88 | CYP2C19 (0.38) | CYP2C19POLBBLMATM | |
| SCHEMBL17883360 | 0.86 | CYP2C19 (0.46) | CYP2C19POLBBLMATM | |
| SCHEMBL19999151 | 0.86 | CYP2C19 (0.46) | CYP2C19POLBBLMATM | |
| SCHEMBL5596429 | 0.84 | — | — | |
| SCHEMBL15890591 | 0.80 | CYP2C19 (0.41) | CYP2C19POLBBLMATM | |
| SCHEMBL15890590 | 0.80 | TSHR (0.46) | CYP2C19POLBBLMATM | |
| SCHEMBL5596714 | 0.79 | TDP1 (0.31) | CYP2C19 | |
| SCHEMBL888204 | 0.78 | MEN1 (0.48) | CYP2C19POLBBLMATM | |
| SCHEMBL13301154 | 0.78 | MEN1 (0.48) | CYP2C19POLBBLMATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | CYP2C19 4112/4885POLB 2903/4885BLM 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.